select a format

Single User License
USD 250 INR 16010
Site License
USD 500 INR 32020
Corporate User License
USD 750 INR 48030

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Mylan NV (MYL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Mylan NV (MYL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH31565D
  • |
  • Pages: 143
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines and consumer healthcare products. It offers pharmaceutical products in multiple forms across therapeutic categories such as respiratory and allergy, cardiovascular, central nervous systems, infectious disease, oncology, anesthesia and others. Mylan sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. It has presence in North America, Europe, the Middle East and Africa, and other countries. Mylan is headquartered in Hatfield, Hertfordshire, the UK.

Mylan NV (MYL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Mylan NV, Medical Devices Deals, 2011 to YTD 2017 13

Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Mylan NV, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 19

Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 19

Teva Pharma May Divest its Assets 21

Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 22

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 24

Mylan to Acquire Rights to Arixtra Injection from Aspen Global 26

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 27

Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 29

Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For US$30 Million 30

Rottapharm|Madaus Acquires Zyma Brands 31

Meda Acquires OTC Sleep Aid Product, MidNite 32

Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For US$33 Million 33

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million 34

Meda Acquires Ceplene From EpiCept For US$3 Million 36

Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 37

Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For US$348 Million 38

Meda Acquires Rights to Three Nordic OTC Drugs from McNeil and Cilag for USD111 Million 39

Meda Completes Acquisition Of Global Rights To Elidel From Novartis For US$420 Million 40

Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline 41

Private Equity 42

Riverside Acquires Euromed from Meda for USD86.7 Million 42

Partnerships 43

Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 43

Mabion Enters into Distribution Agreement with Mylan 44

Pulmatrix Enters into Co-Development Agreement with Mylan 45

AB-Biotics Enters into Distribution Agreement with Mylan 46

Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 47

Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 47

Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 48

Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 49

Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 50

Meda Expands Co-Development Agreement With Cipla For Dymista 51

Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 52

Agila Specialties Forms Joint Venture With Jamp Pharma 53

Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 53

Matrix Labs Plans Co-Marketing Agreement For 100 Products 54

Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 55

Licensing Agreements 56

Mylan Enters into Licensing Agreement with Genentech and Roche 56

Mylan Enters into Licensing Agreement with Medicines Patent Pool 57

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 57

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 58

Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 59

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 60

Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 60

Gilead Sciences Expands Licensing Agreement with Mylan Labs 62

Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 63

Gilead Sciences Enters into Licensing Agreement with Mylan Labs 64

Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 65

Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 66

Mylan Enters Into Licensing Agreement With Orion for Stalevo 66

Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 67

Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 68

Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 69

Moberg Pharma Amends Licensing Agreement with Meda 70

Meda Enters Into Licensing Agreement With Moberg Derma For Nalox 71

Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 72

Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese 74

Meda Amends Licensing Agreement With Medivir For Xerese 75

Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 76

Equity Offering 77

Abbott Prices Public Offering of Shares of Mylan for USD2 Billion 77

Meda to Raise USD278.7 Million in Rights Offering 78

Rottapharm Withdraws IPO for USD614.7 Million 80

Debt Offering 81

Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 81

Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 82

Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 82

Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 83

Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 84

Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 85

Mylan Completes Public Offering Of Notes Due 2043 For US$500 Million 85

Mylan Completes Public Offering Of Notes Due 2016 For US$500 Million 87

Mylan Completes Public Offering Of Notes Due 2023 For US$500 Million 88

Mylan Completes Public Offering Of Notes Due 2019 For US$500 Million 89

Mylan Completes Private Placement Of Notes Due 2018 For US$650 Million 90

Mylan Completes Private Placement Of Notes Due 2016 For US$500 Million 91

Meda Prices Public Offering Of Notes Due 2016 For US$62 Million 92

Meda Prices Public Offering Of Notes Due 2018 For US$92.4 Million 93

Mylan Completes Private Placement Of Notes Due 2023 For US$750 Million 93

Acquisition 94

Mylan Acquires Meda for USD9.9 Billion 94

Teva Pharma, Mylan May Acquire Teut|Pfizer 97

Meda Acquires Rottapharm from Fidim for USD3 Billion 98

Fidim Acquires Rottapharm Biotech from Rottapharm 99

Meda Acquires ZpearPoint, Dental Products Provider 100

Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To US$1.75 Billion 101

Mylan Rumored To Acquire Bafna Pharma 103

Meda Completes Acquisition Of Acton Pharma For Up To US$200 Million 104

Mylan Acquires Synerx Pharma, Generic Maker 105

Meda Completes Acquisition Of Antula From Healthcare Brands 106

Mylan NV-Key Competitors 108

Key Employees 109

Locations And Subsidiaries 110

Head Office 110

Other Locations & Subsidiaries 110

Recent Developments 117

Financial Announcements 117

May 10, 2017: Mylan Reports First Quarter 2017 Results 117

Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 119

Nov 09, 2016: Mylan Reports Third Quarter 2016 Results 121

Aug 09, 2016: Mylan Reports Strong Second Quarter 2016 Results Including Total Revenues Up 8% 125

May 03, 2016: Mylan Reports Strong First Quarter 2016 Earnings Results Including Total Revenues Up 17% 128

Feb 10, 2016: Mylan Full Year Adjusted Diluted EPS Up 21% to $4.30 130

Corporate Communications 133

May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 133

Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 134

Jun 23, 2016: Mylan Donates 1 Million to the Princess Mxima Center for Pediatric Oncology 135

May 03, 2016: Mylan Names Kenneth Parks Chief Financial Officer 136

Feb 22, 2016: Mylan Appoints Anthony Mauro Chief Commercial Officer 137

Feb 22, 2016: Mylan CEO Heather Bresch Elected Chair of Generic Pharmaceutical Association 138

Jan 08, 2016: Mylan CFO John Sheehan to Retire as of April 1, 2016 139

Legal and Regulatory 140

Aug 25, 2016: Teva Plunges After Two U.S. Copaxone Patents Invalidated 140

Product News 141

Nov 29, 2016: New ADEKplus a Fat Soluble Nutritional Product Launched to Aid Conditions Such as Cystic Fibrosis 141

Product Approvals 142

Jan 11, 2016: Mylan Confirms FDA Submission of ANDA for Generic Advair Diskus 142

Appendix 143

Methodology 143

About GlobalData 143

Contact Us 143

Disclaimer 143

List of Figures

Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Mylan NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 9

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Mylan NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11

Mylan NV, Medical Devices Deals, 2011 to YTD 2017 13

List of Tables

Mylan NV, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Mylan NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8

Mylan NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9

Mylan NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10

Mylan NV, Deals By Therapy Area, 2011 to YTD 2017 11

Mylan NV, Medical Devices Deals, 2011 to YTD 2017 13

Mylan NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14

Mylan Acquires Global Rights to Cold-EEZE Brand from ProPhase Labs 19

Mylan Acquires Topical Pharmaceutical Business of Renaissance for up to USD1 Billion 19

Teva Pharma May Divest its Assets 21

Mylan Acquires Female Health Care Businesses from Famy Care for USD800 Million 22

Mylan Acquires Branded Generics Business of Abbott for USD5.3 Billion 24

Mylan to Acquire Rights to Arixtra Injection from Aspen Global 26

Sanofi Plans to Sell Portfolio of Mature Drugs for USD8.6 Billion 27

Mylan Acquires Rights To Lama Respiratory Compound From Pfizer 29

Mylan Completes Acquisition Of Drug Manufacturing Plant From Unichem For US$30 Million 30

Rottapharm|Madaus Acquires Zyma Brands 31

Meda Acquires OTC Sleep Aid Product, MidNite 32

Mylan Labs To Acquire Manufacturing Unit Of SMS Pharma For US$33 Million 33

Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million 34

Meda Acquires Ceplene From EpiCept For US$3 Million 36

Mylan Acquires Clindamycin Phosphate And Benzoyl Peroxide Gel From Valeant Pharma International 37

Mylan Completes Acquisition Of Respiratory Delivery Platform From Pfizer For US$348 Million 38

Meda Acquires Rights to Three Nordic OTC Drugs from McNeil and Cilag for USD111 Million 39

Meda Completes Acquisition Of Global Rights To Elidel From Novartis For US$420 Million 40

Meda Acquires Two Additional OTC Products In US From GlaxoSmithKline 41

Riverside Acquires Euromed from Meda for USD86.7 Million 42

Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 43

Mabion Enters into Distribution Agreement with Mylan 44

Pulmatrix Enters into Co-Development Agreement with Mylan 45

AB-Biotics Enters into Distribution Agreement with Mylan 46

Mylan Pharma Enters into Distribution Agreement with Gilead Sciences 47

Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 47

Meda Enters Promotion Agreement With Mission Pharmacal For Elestrin 48

Mylan Pharma Enters Into Distribution Agreement With Gilead Sciences 49

Venus Pharma Enters Into Co-Marketing Agreement With Mylan For Meropenem 50

Meda Expands Co-Development Agreement With Cipla For Dymista 51

Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 52

Agila Specialties Forms Joint Venture With Jamp Pharma 53

Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 53

Matrix Labs Plans Co-Marketing Agreement For 100 Products 54

Bristol-Myers Squibb Enters Into Co-Marketing Agreement With Matrix Labs 55

Mylan Enters into Licensing Agreement with Genentech and Roche 56

Mylan Enters into Licensing Agreement with Medicines Patent Pool 57

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 57

Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 58

Mylan Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 59

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 60

Mylan Ireland Enters into Licensing Agreement with Momenta Pharma 60

Gilead Sciences Expands Licensing Agreement with Mylan Labs 62

Gilead Sciences Enters into Licensing Agreement with Mylan Labs for Tenofovir Alafenamide 63

Gilead Sciences Enters into Licensing Agreement with Mylan Labs 64

Venus Pharma Enters into Licensing Agreement with Mylan for Meropenem 65

Prosonix Enters Into Licensing Agreement With Mylan For PSX1001 And PSX1050 66

Mylan Enters Into Licensing Agreement With Orion for Stalevo 66

Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 67

Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 68

Mylan Labs Enters Into Licensing Agreement With Gilead Sciences For Generic Versions Of Emtricitabine 69

Moberg Pharma Amends Licensing Agreement with Meda 70

Meda Enters Into Licensing Agreement With Moberg Derma For Nalox 71

Gilead Sciences Extends Licensing Agreement With Matrix Labs For Tenofovir, Elvitegravir, Cobicistat And Quad 72

Valeant Pharma Enters Into Licensing Agreement With Meda For Elidel And Xerese 74

Meda Amends Licensing Agreement With Medivir For Xerese 75

Tibotec Pharma Enters Into Licensing Agreement With Matrix Labs For TMC278 76

Abbott Prices Public Offering of Shares of Mylan for USD2 Billion 77

Meda to Raise USD278.7 Million in Rights Offering 78

Rottapharm Withdraws IPO for USD614.7 Million 80

Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 81

Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 82

Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 82

Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 83

Mylan Raises USD500 Million in Private Placement 3.75% Notes Due 2020 84

Mylan Raises USD500 Million in Private Placement 3% Notes Due 2018 85

Mylan Completes Public Offering Of Notes Due 2043 For US$500 Million 85

Mylan Completes Public Offering Of Notes Due 2016 For US$500 Million 87

Mylan Completes Public Offering Of Notes Due 2023 For US$500 Million 88

Mylan Completes Public Offering Of Notes Due 2019 For US$500 Million 89

Mylan Completes Private Placement Of Notes Due 2018 For US$650 Million 90

Mylan Completes Private Placement Of Notes Due 2016 For US$500 Million 91

Meda Prices Public Offering Of Notes Due 2016 For US$62 Million 92

Meda Prices Public Offering Of Notes Due 2018 For US$92.4 Million 93

Mylan Completes Private Placement Of Notes Due 2023 For US$750 Million 93

Mylan Acquires Meda for USD9.9 Billion 94

Teva Pharma, Mylan May Acquire Teut|Pfizer 97

Meda Acquires Rottapharm from Fidim for USD3 Billion 98

Fidim Acquires Rottapharm Biotech from Rottapharm 99

Meda Acquires ZpearPoint, Dental Products Provider 100

Mylan Completes Acquisition Of Agila Specialties From Strides Arcolab For Up To US$1.75 Billion 101

Mylan Rumored To Acquire Bafna Pharma 103

Meda Completes Acquisition Of Acton Pharma For Up To US$200 Million 104

Mylan Acquires Synerx Pharma, Generic Maker 105

Meda Completes Acquisition Of Antula From Healthcare Brands 106

Mylan NV, Key Competitors 108

Mylan NV, Key Employees 109

Mylan NV, Other Locations 110

Mylan NV, Subsidiaries 111

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Mylan NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com